Glenmark Pharmaceuticals has informed about a Press Release dated January 08, 2016 titled ‘Glenmark announces the Discovery and Initiation of IND-enabling studies of a novel bi-specific monoclonal antibody targeting CD38’.
The above information is a part of company’s filings submitted to BSE.